AMD

AMD treatment may become unrecognizable as gene therapies evolve.

Research reveals significant vision improvements and extended treatment intervals with aflibercept 8 mg for age-related macular degeneration and diabetic edema patients.

The investigators noted that this report is the first about subretinal drusenoid deposits in Black and Hispanic patients with age-related macular degeneration.

Data suggests the candidate can reduce the number of injections and treatment burden for patients

EYDENZELT is Celltrion's first FDA-approved biologic product in ophthalmology.

Sura-vec is intended to be a potential 1-time treatment consisting of the NAV AAV8 vector, which encodes an antibody fragment designed to inhibit vascular endothelial growth factor (VEGF).

Holz discusses advancements in retinal disease treatments at the EURETINA meeting, featuring gene therapy and innovative implants to enhance patient care.

Patricio Schlottmann highlights promising long-term results of faricimab for wet AMD, showcasing sustained visual gains and excellent safety in patients.

Miere discusses retinal studies on AMD and vein occlusion, highlighting imaging advancements and the future of machine learning in treatment predictions.

This new technology, the MacuMira system, is a non-invasive treatment now available in more than 150 clinics across Canada.

In honor of looking back at 50 years, we look forward at a world where the toughest eye diseases could be cured in the blink of an eye.

EYLUXVI (ALT-L9) is an aflibercept (Eylea) biosimilar from Alteogen, co-developed by its subsidiary, Alteogen Biologics.

Alteogen received a positive CHMP opinion for EYLUXVI in July 2025.

Character Biosciences enhances its leadership team and secures $93 million in Series B funding to advance treatments for degenerative eye diseases.

Guymer discusses early intervention strategies for intermediate AMD, highlighting risk factors, and potential trial designs to prevent vision loss.

The ultimate goal of redefining endpoints is enabling earlier diagnosis and treatment, said Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS

Kalaris Therapeutics initiates a phase 1b/2 study for TH103, targeting neovascular age-related macular degeneration and advancing retinal disease treatment.

The company’s lead clinical-stage program, OLN324, is a higher potency, higher molar dose VEGF/Ang2 bispecific antibody currently in phase 1b clinical development for patients with either wAMD or DME.

Belite Bio completes its phase 3 trial for tinlarebant, a potential first treatment for Stargardt disease, with results expected in late 2025.

Optain Health secures $26 million in Series A funding to enhance AI-driven retinal disease detection and expand its technology.

Researchers conducted this study to determine how often and why spontaneous soft drusen regresses without atrophy in patients who had intermediate or atrophic age-related macular degeneration.

Researchers will investigate a gene in the eye that is crucial for normal vision, but can cause retinal diseases when mutated that often lead to blindness.